What is Vaxess Technologies?
Vaxess Technologies is at the forefront of biomedical innovation, developing a proprietary transdermal patch and applicator designed for the convenient delivery of a wide range of therapies and vaccines. The company envisions a future where essential medical treatments can be administered at home or in resource-limited settings without the need for needles or refrigeration. This transformative approach is driven by a diverse team of life scientists, engineers, and entrepreneurs who integrate expertise in chemistry, biology, immunology, and mechanical and biomedical engineering to create healthcare solutions that offer unprecedented accessibility and ease of use.
How much funding has Vaxess Technologies raised?
Vaxess Technologies has raised a total of $158.9M across 10 funding rounds:
Private Equity
$862K
Series A
$82M
Debt
$150K
Series B
$27M
Other Financing Round
$10M
Other Financing Round
$9M
Other Financing Round
$12M
Other Financing Round
$9M
Debt
$7.9M
Private Equity (2016): $862K, investors not publicly disclosed
Series A (2019): $82M supported by The Engine and Bioinnovation Capital
Debt (2020): $150K featuring PPP
Series B (2022): $27M backed by Mission BioCapital, Global Health Investment Corporation, and The Engine
Other Financing Round (2023): $10M with participation from RA Capital Management and Mission BioCapital
Other Financing Round (2023): $9M led by RA Capital Management, Ulu Ventures, and The Engine
Other Financing Round (2024): $12M supported by RA Capital Management, Engine Ventures, and Mission BioCapital
Other Financing Round (2025): $9M featuring RA Capital Management and Engine Ventures
Debt (2025): $7.9M, investors not publicly disclosed
Key Investors in Vaxess Technologies
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies. They aim to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives.
Mission BioCapital
Mission BioCapital is a venture capital firm that provides early-stage capital to innovative life science entrepreneurs, focusing on empowering startups through mentorship and collaboration to accelerate scientific solutions.
The Engine
The Engine, built by MIT, is a venture firm investing in the next generation of Tough Tech, applying cutting-edge technology to solve challenges in human health, climate change, and advanced systems.
What's next for Vaxess Technologies?
With substantial enterprise-level backing and recent strategic investments, Vaxess Technologies is poised for significant expansion. The company's focus on a needle-free, refrigeration-free delivery system addresses critical global health challenges, including vaccine accessibility in remote areas and the convenience of self-administered treatments. Future developments will likely concentrate on clinical validation, manufacturing scale-up, and broader market penetration. The ongoing capital infusion signals strong investor confidence in Vaxess's potential to disrupt traditional healthcare delivery models and establish a new standard for therapeutic and vaccine administration.
See full Vaxess Technologies company page
